BIOMAT Database Logo BIOMAT Database Logo

Cardiovascular function in a chronic peritoneal dialysis pediatric population on recombinant human erythropoietin treatment. 1993

S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Department of Nephrology, Children's Hospital, Brescia, Italy.

Anemia, through a hyperkinetic state, is an important contributor to myocardial function impairment. To determine the cardiovascular effects of recombinant human erythropoietin (rHuEPO) therapy, 10 chronic peritoneal dialysis (CPD)-treated anemic children were studied before and during 18 months of treatment. The following parameters were recorded: hemoglobin (Hb) [percent of target level (TL) = x-2 standard deviations of normal Hb values for age and sex], heart rate (HR, beats/minute), mean arterial pressure (MAP, mmHg), end-diastolic left ventricular diameter (EDLVD, mm/sm BSA), shortening fraction (SF, percent), and interventricular septal thickness (IVS, mm/sm BSA). Student's t-test for paired data showed (vs time before treatment, T0) a progressive increase in Hb, a progressive decrease in HR, and a progressive increase in MAP. EDLVD progressively decreased, while SF and IVS remained unchanged throughout the study. Regression analysis showed a close correlation between anemia correction and decrease of HR (p < 0.01), while no correlation was found between Hb and EDLVD or SF, IVS, or MAP. Our data indicate that anemia correction in these patients is mainly associated with a decrease in hyperkinetic state (HR reduction with SF unvaried), while left ventricular function and dimensions remain normal, despite an increase in MAP.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females

Related Publications

S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Recombinant human erythropoietin in patients on peritoneal dialysis.
January 1989, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Recombinant human erythropoietin and peritoneal dialysis.
June 1990, The International journal of artificial organs,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis.
January 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis.
November 1991, Pediatric nephrology (Berlin, Germany),
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Subcutaneous recombinant human erythropoietin treatment of children undergoing peritoneal dialysis.
January 1991, Contributions to nephrology,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure.
January 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
February 1989, Lancet (London, England),
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients.
January 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Intra peritoneal use of recombinant human erythropoietin for the treatment of anemia in intermittent peritoneal dialysis.
January 1991, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
S Bassi, and G Montini, and A Edefonti, and F Perfumo, and D Cattarelli, and G Piaggio, and V Fesslova, and G Zacchello, and S Bove
Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis.
July 1992, European journal of pediatrics,
Copied contents to your clipboard!